US FDA approved first oral drug to reduce Multiple Sclerosis MS relapses
The United States F D A approved new drug to treat Multiple Sclerosis.
Gilenya capsules containing fingolimod as active molecule is approved by US FDA on 22-09-2010 for treatment of Multiple Sclerosis, the drug can be used to reduce relapses and delay disability progression in patients affected with relapsing forms of multiple sclerosis (MS).
Gilenya (fingolimod) is the first oral drug that can delay the progression of disability and lessen the frequency and severity of symptoms of multiple sclerosis (MS) it is an option for at present available injectable therapies.
Information about multiple sclerosis (MS):
Multiple sclerosis MS is disease condition which is a chronic, often disabling, disease which affects the central nervous system—the brain, spinal cord, and optic nerves , where a normal communication from central nervous system to other parts of body is disturbed resulting in to disability of the body part affected.
It is developed due to autoimmune disease condition where body’s own defense mechanism attacks its own body tissues , here in case of Multiple sclerosis mylin sheth that covers nerve fiber becomes target of auto immune attack.
The progress, severity, and specific symptoms of MS are unpredictable and may vary from one person to person. Symptoms may be mild, like numbness in the limbs, or may be as severe as paralysis or loss of vision.
Fingolimod is chemically derived from myriocin a antibiotic and a metabolite from fungus Isaria sinclairii.
Fingolimod molecule is structurally similar to sphingosine.
Sphingosine a constituent of sphingolipids , that form cell membrane lipids constituting sphingomyelin.
And sphingomyelin play a vital role in producing chemical signals which are responsible for many cellular process activation, one of which is activation of lymphocyte and migration in immune reactions.
Fingolimod owning to structural similarity with sphingosine get phosphorylated instead of sphingomyelin.
and it is responsible for blocking lymphocytes in lymph nodes thereby preventing them from getting in to central nervous system, brain and spinal cord
Thus Fingolimod blocks lymphocytes in lymph nodes thereby preventing them from getting in to central nervous system, brain and spinal cord, lymphocytes mediate auto immune responses , some of the immune responses mediated by lymphocytes are autoimmune and are harmful to patients affected with multiple sclerosis (MS).
Drug Gilenya (fingolimod) is found to be reducing the severity of multiple sclerosis (MS).
FDA said in its press release that patients using Gilenya must be monitored for a decrease in heart rate upon starting the drug.
As Gilenya reduces immune response it is likely that there is a risk getting infections.
US FDA also recommend an ophthalmologic evaluation as in some cases serious eye problems (macular edema) are reported in patients taking the drug Gilenya.
Reported in clinical trial in patients taking Gilenya are headache, influenza, diarrhea, back pain, elevation of certain liver enzymes and cough.
The drug will be available as capsules of strength 0.5 milligram.
Gilenya is made by Pharmaceutical Manufacturing Company from Switzerland Novartis, Basel, Switzerland.
Congratulations to Novartis, Basel, Switzerland.
Do you know now this website has become a most popular and most referred website in pharmaceutical industry and pharmaceutical companies and pharmaceutical manufacturers from all over the world ,for almost all topics related to Pharmaceutical Manufacturing , Pharmaceutical Regulatory Affairs and Good Manufacturing Practice for Pharmaceutical Manufacturing (c GMP guidelines ) and latest news and new drugs developments.
You may also like following articles
What is Pharmaceutical Equivalents
What is Pharmaceutical Alternatives
What is Therapeutic Equivalents
What is What is 510(k) Clearances ?
Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.
Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in
Good manufacturing practice in pharmaceutical industry
Pharmaceutical industry pharmaceutical companies and FDA latest updates
Here is an interesting article on world wide pharmaceutical industry and making a carrier in one of pharmaceutical companies article on Pharmaceutical Industry pharmaceutical industry
Find a Job in Pharmaceutical Company
To Find Pharmaceutical jobs and make a Pharmaceutical careers see here pharmaceutical companies
Here are some interesting articles on Quality assurance systems for pharmaceutical company
2.Quality by designe concept for pharmaceutical industry
3.Quality by designe concept in pharmaceutical industryan explanation